2021年4月～10月の糖尿病関連論文
勤務先で週1回やっている抄読会で、ここ半年に自分が取り上げた論文を見返してみました。
治療薬で印象的だったのは、Insulin Icodec (週1回注射）、Tirzepatide（週1回のGLP1/GIPのco agonist)、Bimagrumab(ミオスタチン受容体拮抗薬）、Finerenone（MR blocker）。
逆にがっかりだったのはCotadutide（GLP1/glucagoneのco agonist)。
以下論文リスト
糖尿病治療関連
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
Diabetes Care 2021;44:1-9
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
Diabetes Care 2021;44:1595-1603
Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type2 Diabetes Treated With Basal Insulin. A randomized Clinical Trial.
JAMA published online June2, 2021
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.
Diabetes Care 2021:44:1-11
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placet-Controlled, Paraless-Group, Multicenter Phase 3 Trial.
Diabetes Care 2021;44:952-959
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Diabetes Care 2021;44:1433-1442
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Dabetes and Obesity.
JAMA Network Open 2021;4(1) e2033457
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
NEJM published on June 25, 2021
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
NEJM published on June 28, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
NEJM published on August 28, 2021
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice; The Japan Chronic Kidney Disease Database.
Diabetes Care published online September 30, 2021
臨床疫学・研究
Predicting major adverse limb events in individuals with type 2 diabetes; Insights from the EXCEL trial.
Diabetic Medicine 2021;00e14552
Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.
Diabetes Care 2021;44:1-9
Risk Factors for Incident Fracture in Older Adults With Type 2 Diabetes; The Framingham Heart Study.
Diabetes Care 2021;44:1-9
Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies.
Narure communications 2021 https://doi .org/10.1038/s41467-021-22370-2
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes; Results From the ADVANCE Trial.
Diabetes Care 2021;44:1-8
Long-Term Complications in Youth-Onset Type 2 Diabetes,
NEJM 2021;385:416-26
総説
Obesity management as a primary treatment goal for type 2 diabetes; time to reframe the conversation.
Lancet published online September 30, 2021
Novel therapies with precision mechanisms for type 2 dabetes mellitus.
Nature Review Endocrinology https://doi,org/10.1038/s41574-021-00489.y
Preparing for the NASH Epidemic; A Call to Action,
Diabetes Care 2021;44:2162-2172
心血管・血圧
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes.
JACC Heart Failure 2021;9:215-23
High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study,
Diabetes Care published online May 5, 2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction,
NEJM 2021;385:1451-61
Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension. A Randomized Clinical Trial,
JAMA Cardiology published online August 4, 2021
Effect of Salt Substitution on Cardiovascular Events and Death,
NEJM published on August 29, 2021